home · filing · 0000950170-23-011915
8-K filed April 5, 2023, 7:59 PM ET
ticker SRZN
CIK 0001824893
leadership
confidence high
sentiment neutral
materiality 0.45
Surrozen appoints Eric Bjerkholt as Class I director and audit committee member
Surrozen, Inc./DE
Eric Bjerkholt appointed to board as Class I director effective April 5, 2023.
He will serve on the audit committee.
Bjerkholt is CFO of Chinook Therapeutics; previously CFO of Aimmune, leading its $2.6B sale to Nestle.
Compensation: $35,000 annual retainer, $7,500 audit retainer, initial option grant of 40,000 shares vesting over 36 months.
Standard indemnification agreement entered with Bjerkholt.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Eric Bjerkholt
Class I Director
Effective 2023-04-05
Filed April 5, 2023, 7:59 PM ET
On April 5, 2023, the board of directors of Surrozen, Inc. appointed Eric Bjerkholt to serve as a Class I director
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eric Bjerkholt was appointed as Class I Director at Surrozen, Inc./DE.
Action appointed
Role Class I Director
Exact text from the filing
On April 5, 2023, the board of directors of Surrozen, Inc. appointed Eric Bjerkholt to serve as a Class I director
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-23-011915
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.